The company's shares have fallen 5% over the past month amid pricing concerns and competition in the obesity drug market. However, strong sales of its key products Mounjaro and Zepbound continue, and its growth prospects are supported by a deep pipeline. The company has launched a new platform to expand employer-based access to its obesity medicines and reported positive Phase 3 results for its oral GLP-1 drug candidate. It also received a positive European regulatory opinion for Olumiant in adolescents.